Laronde Funding & Investors
Cambridge, MA
Laronde is pioneering a platform that offers a completely novel way of modulating human biology. Endless RNAβ’ (eRNA), is a uniquely engineered RNA that can be programmed to express diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery. Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidly scaling to support the parallel development of multiple programs across many disease areas.
laronde.bioTotal Amount Raised: $490,000,000
Laronde Funding Rounds
Series B
$440,000,000
Series B Investors
Flagship PioneeringCPP InvestmentsFidelity InvestmentsFederated Kaufmann FundT. Rowe PriceInvus GroupBlackRockLVFSeries A
$50,000,000
Series A Investors
Flagship Pioneering
Funding info provided by Diffbot.